ACC 2021 | HOST-EXAM: Clopidogrel vs ASA monotherapy post DAPT in PCI patients

Clopidogrel monotherapy after dual antiplatelet therapy (DAPT) was associated with reduced mortality, MI, stroke, and other events in patients receiving PCI compared against aspirin monotherapy (ASA).

ACC 2021 | HOST-EXAM: Clopidogrel vs AAS como monoterapia post DAPT en las angioplastias

This information was provided by the Korean HOST-EXAM study, presented at ACC 2021 scientific sessions, and simultaneously published in the Lancet.

Researchers followed patients for 2 years and observed consistent results across subgroups, regardless baseline and angiographic characteristics. 

Primary end point, a combination of all cause death, MI, stroke, BARC 3 bleeding or higher, at 24 months, occurred in 5.7% of patients randomized to clopidogrel vs 7.7% of patients randomized to ASA (HR 0.73; IC 95% 0.59 a 0.90).

According to authors, the benefits of clopidogrel were observed both in thrombotic and bleeding terms. However, a longer followup in other populations is necessary (the whole cohort was Korean) to be able to reach more definitive conclusions. 

Guidelines on both sides of the Atlantic recommend ASA at long term after coronary PCI, but these study outcomes challenge ASA.


Read also: ACC 2021 | RAPID-TnT: Usefulness of High-Sensitivity Ultra-Fast Troponin T.


The HOST-EXAM randomized 5530 patients from 37 centers in Korea. All patients were free of events (thrombotic or bleeding) were within 6 to 18 months after coronary PCI and had completed the indicated DAPT period.

At the moment of intervention, over half of patients presented stable angina, 19.4% non-STEMI and 17.2% STEMI.

These new and provocative data raise our expectations for longer followup and similar results across different populations. 

HOST-EXAM

Original Title: Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial.

Reference: Bon-Kwon Koo et al. Presentado en el congreso de la ACC 2021 y publicado simultáneamente en Lancet. https://doi.org/10.1016/S0140-6736(21)01063-1.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...